ADXS - Your Daily Pharma Scoop: Redhill Zooms FDA Nods Advaxis Ahead Hologic Warned
Stocks in News: RDHL, ADXS
RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket
Discussion: RedHill Biopharma’s (RDHL) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the data from placebo was achieved. The statistical difference was significant. Compared to the 23% remission, 37% patients in the drug-treatment group achieved remission at 26th week. Secondary endpoints were also met by the study. Maintenance of remission at 52nd week for those who achieved remission at 26th week was also reportedly superior